🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ESMO21 😍Magnificent overview of extended adjuvant endocrine trelandmark trials in early #breastcancer ESMO - Eur. Oncology #bcsm OncoAlert Lucia Del Mastro

#ESMO21 live on Channel 2 FOLFOXIRI + bev & atezolizumab vs. FOLFOXIRI bev as 1st line tx of #crcsm: Phase II AtezoTRIBE Adding Atezo did increase PFS in the study population! OncoAlert 🚨 ESMO - Eur. Oncology #PrecisionOncology #PrecisionMedicine

A spectacular practice changing benifit for adding abiraterone to RT and ADT for high risk M0 Prostate cancer . 40% !!! Reduction in the risk of death. Congrats to the team

Dr. Antonio Calles 🫁🚭 "Thank goodness we have another combination that gets us results as good as we've had with KEYNOTE-189 and KEYNOTE-407 since 2018", said nobody ever.

Radical trial of radium-223 + cabozantinib for patients with RCC with bone metastases. Currently accruing through the NCTC. ⁦Alliance for Clinical Trials in Oncology⁩ ⁦Kidney Cancer⁩ ⁦KidneyCAN⁩

The landscape of HR+ metastatic #breastcancer is on the verge of a "big bang" of new agents includ. novel SERD, SERM, SARM, SERCA, CERAN and PROTAC. For a summary see the table below from our recently published review (bit.ly/3EIYgnA) #EndCancer #bcsm OncoAlert

Very important large dataset confirming prior data and clinical observation. We need to rethink the cutoff for HR positivity and also inclusion in trials/Treatment selection. Most very low HR+ disease is basal like.

Lewis et al Big data 1L #DLBCL HDMTX CNS prophylaxis you have been waiting for! CNS IPI 4-6 (>90%) or high risk feature N=2300 HDMTX or nil Well balanced No diff in CNS relapse in any subgp Massive global effort Congrats to all involved Esp Katharine Lewis + Chan Cheah #ASH2021

“They pay to publish their own papers AND to read them!”

The next time that someone in the Ivory Tower perseverates over the value of studies that rely merely on a PFS signal, please share this slide that Jill Feldman created which sheds light on what patients often endure to get that PFS signal. #lcsm #radonc

Beautiful slide.

Excellent focused review on disparities in germline testing in men with prostate cancer led by Nicole Weise. Highlighting challenges and solutions to germline testing. ⁦UC San Diego Health⁩ ⁦UC San Diego Research and Innovation⁩ nature.com/articles/s4139…

Agree we need to focus on the imp question of when,if, and in whom, we can stop rx. We don’t have 20 years to repeat Intermittent v continuous ADT question. Novel trial design is the way Atish Choudhury, MD PhD Alicia Morgans, MD, MPH

We are excited to welcome our new class of #HemOnc #fellows for 2022! Welcome to the UCSD Hematology/Oncology Fellowship , UCSD Internal Medicine Residency, and UC San Diego Health family! #MatchDay

Practice changing - new reference intervals for serum FLC and FLC ratio for use in patients with CKD from iStopMM #mmsm #ASH21 ash.confex.com/ash/2021/webpr…

Where are we after 20 years of R-CHOP in DLBCL? Update from #ASH21 with the POLARIX trial demonstrating a PFS benefit with pola-R-CHP vs R-CHOP (HR 0.73; p<0.02) but no difference in OS. #lymsm

Don’t know who needs to hear this but NCCN guidelines are just guidelines- not mantra that you should religiously adhere to. You can read the underlying study by yourself. Not following the NCCN guidelines is not a sub-standard practice as long as it’s an informed decision.

In this JNCI Commentary, Drs. Freidlin and Korn of @NCItreatment National Cancer Institute explore a commonly used #phaseIII #clinicaltrial design that may result in recommending new therapies to #biomarker-negative patients when these therapies are no benefit to them bit.ly/3AgU6j4

When will the current omicron wave be considered “bad enough” to allow us once again to practice telemedicine across state lines?? (1/4)

Our FDA Oncology pooled patient-level analysis of safety of radiation used within 90 days of immunotherapy in a cohort of ~17,000 published in JAMA Oncology, previously presented as a poster discussion ASCO Shaily Arora Laleh Amiri-Kordestani, MD jamanetwork.com/journals/jamao…